Sept 29 (Reuters) – CSPC PHARMACEUTICAL GROUP LIMITED : * PHARMA'S RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS FDA CLINICAL TRIAL APPROVAL IN U.S. Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Ryan Patrick Jones TORONTO, Sept 29 (Reuters) - Three generations of an Armenian-Christian family…
VIDEO SHOWS: SOUNDBITES FROM FORMER WORLD NUMBER EIGHT AND JAPAN'S KEI NISHIKORI AHEAD OF HIS…
By Waylon Cunningham NEW YORK, Sept 29 (Reuters) - McDonald’s is increasingly using artificial intelligence…
By Echo Wang, Ross Kerber and Jeffrey Dastin Sept 28 (Reuters) - Anthropic has long…
INDIAN RUPEE ENDS NEARLY FLAT AT 95.98 PER U.S. DOLLAR VERSUS PREVIOUS CLOSE AT 95.9825…
CHINA CENTRAL BANK: RAISES PRIVATE ENTERPRISE RELENDING QUOTA BY 300 BLN YUAN TO 1.3 TRLN…